Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are widely used in the healthcare industry to prevent excessive bleeding during surgeries or trauma. Hungary, being a part of the European Union, has a well-established healthcare system that is open to modern medical practices. The market for Anti-Fibrinolytic Drugs in Hungary has been growing steadily over the years, owing to various factors.
Customer preferences: Customers in Hungary are becoming more aware of the benefits of Anti-Fibrinolytic Drugs and are increasingly opting for these drugs during surgeries. With the rise in the number of surgeries and trauma cases, the demand for these drugs has been increasing steadily.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Hungary is the increasing use of these drugs in cardiac surgeries. The number of cardiac surgeries has been increasing over the years, and Anti-Fibrinolytic Drugs are being used to prevent excessive bleeding during these surgeries. Another trend in the market is the increasing use of these drugs in trauma cases. With the rise in the number of accidents and trauma cases, the demand for these drugs has been increasing steadily.
Local special circumstances: One of the special circumstances in Hungary is the high prevalence of cardiovascular diseases. Hungary has one of the highest rates of cardiovascular diseases in Europe, which has led to an increase in the number of cardiac surgeries. Another special circumstance is the high rate of accidents and trauma cases. Hungary has a high rate of road accidents, which has led to an increase in the number of trauma cases.
Underlying macroeconomic factors: The healthcare system in Hungary is well-established and is open to modern medical practices. The government has been investing heavily in the healthcare sector, which has led to the development of modern medical facilities. The rise in the number of surgeries and trauma cases has also contributed to the growth of the Anti-Fibrinolytic Drugs market in Hungary. Additionally, the increasing awareness among customers about the benefits of these drugs has led to an increase in demand.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
